Warning  Please take our Crypto Currency survey here
London South East Logo | UK Share Price information



Register
Login:
Share:
Email Facebook Twitter




Immupharma Share Chat (IMM)



Share Price: 153.50Bid: 153.50Ask: 155.00Change: -1.00 (-0.65%)Faller - Immupharma
Spread: 1.50Spread as %: 0.98%Open: 158.00High: 158.00Low: 151.75Yesterday’s Close: 154.50


Share Discussion for Immupharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


YTSS
Posts: 41
Off Topic
Opinion:No Opinion
Price:153.50
RE: Success rates (novel compounds)
Wed 23:20
Do most on here hold shares or leveraged products, assuming you can buy CFDs or similar.? It appears you can set stop losses on CFDs but not shares. If i knew now if available i would have bought CFDs. What disadvantages are tbere in holdIng CFDs ? Assumimg we receive no prior notice of date of results, and they are not good what options are there, if any, for selling v quickly
'
 
Andle
Posts: 48
Off Topic
Opinion:No Opinion
Price:153.50
RE: Success rates (novel compounds)
Wed 17:37
Thanks for the info J4ams and L0ngterm.
Andle
Posts: 48
Off Topic
Opinion:No Opinion
Price:153.50
RE: Phase III Trials
Wed 17:36
Thanks for the link Fritz. Nice bit of light reading it is then before bedtime!!
J4ams
Posts: 341
Off Topic
Opinion:No Opinion
Price:153.50
RE: Success rates (novel compounds)
Wed 17:18
Thanks longterm.
So 64% average success rate for this type of drug. FDA backing, excellent phase IIb results and continued safety in Phase III. This must put us with a very good chance of success.
Hopefully a update RNS imminent.
L0ngterm
Posts: 95
Off Topic
Opinion:No Opinion
Price:154.50
Success rates (novel compounds)
Wed 16:39
Multiple studies have been conducted and depending upon how you dissect the source data different stats can be produced. The below is for novel compounds, which lupuzor is one of.

Hope this helps

“examined more than 9,200 novel compounds that were developed from 1996 through 2014.”

“From 2012 through 2014, the likelihood that a Phase 3 study would advance to product registration was 64 percent, up from 60 percent during the previous three-year period.”

https://www.statnews.com/pharmalot/2016/06/13/clinical-trials-drug-development/
J4ams
Posts: 341
Off Topic
Opinion:No Opinion
Price:154.00
RE: Phase III Trials
Wed 16:17
Thank you Frits
Frits
Posts: 624
Observation
Opinion:Strong Buy
Price:153.50
Phase III Trials
Wed 14:29
The following link has a good PDF on the probability of success.

https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

Res Dog
zedy
Posts: 584
Off Topic
Opinion:No Opinion
Price:154.00
RE: Volume down volatility up.
Wed 14:22
Oilbagger. Thanks for the info. All indications are good news ahead. GLA
Andle
Posts: 48
Off Topic
Opinion:No Opinion
Price:154.25
RE: End of Phase III
Wed 13:44
Poster Sicilian Khan had a good handle on all this. Hasn’t posted for a while now though.
J4ams
Posts: 341
Off Topic
Opinion:No Opinion
Price:154.25
RE: End of Phase III
Wed 13:43
If you Google phase 3 clinical trial success rates, lots of data comes up. Worth a look.
These are figures based on my own research, could be wrong. I would be interested to know if anyone else has a view on probability success?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.